BACKGROUND: Secretoneurin is a neuropeptide located in nerve fibers along blood vessels, is upregulated by hypoxia, and induces angiogenesis. We tested the hypothesis that secretoneurin gene therapy exerts beneficial effects in a rat model of myocardial infarction and evaluated the mechanism of action on coronary endothelial cells. METHODS AND RESULTS: In vivo secretoneurin improved left ventricular function, inhibited remodeling, and reduced scar formation. In the infarct border zone, secretoneurin induced coronary angiogenesis, as shown by increased density of capillaries and arteries. In vitro secretoneurin induced capillary tubes, stimulated proliferation, inhibited apoptosis, and activated Akt and extracellular signal-regulated kinase in coronary endothelial cells. Effects were abrogated by a vascular endothelial growth factor (VEGF) antibody, and secretoneurin stimulated VEGF receptors in these cells. Secretoneurin furthermore increased binding of VEGF to endothelial cells, and binding was blocked by heparinase, indicating that secretoneurin stimulates binding of VEGF to heparan sulfate proteoglycan binding sites. Additionally, secretoneurin increased binding of VEGF to its coreceptor neuropilin-1. In endothelial cells, secretoneurin also stimulated fibroblast growth factor receptor-3 and insulin-like growth factor-1 receptor, and in coronary vascular smooth muscle cells, we observed stimulation of VEGF receptor-1 and fibroblast growth factor receptor-3. Exposure of cardiac myocytes to hypoxia and ischemic heart after myocardial infarction revealed increased secretoneurin messenger RNA and protein. CONCLUSIONS: Our data show that secretoneurin acts as an endogenous stimulator of VEGF signaling in coronary endothelial cells by enhancing binding of VEGF to low-affinity binding sites and neuropilin-1 and stimulates further growth factor receptors like fibroblast growth factor receptor-3. Our in vivo findings indicate that secretoneurin may be a promising therapeutic tool in ischemic heart disease.
BACKGROUND: Secretoneurin is a neuropeptide located in nerve fibers along blood vessels, is upregulated by hypoxia, and induces angiogenesis. We tested the hypothesis that secretoneurin gene therapy exerts beneficial effects in a rat model of myocardial infarction and evaluated the mechanism of action on coronary endothelial cells. METHODS AND RESULTS: In vivo secretoneurin improved left ventricular function, inhibited remodeling, and reduced scar formation. In the infarct border zone, secretoneurin induced coronary angiogenesis, as shown by increased density of capillaries and arteries. In vitro secretoneurin induced capillary tubes, stimulated proliferation, inhibited apoptosis, and activated Akt and extracellular signal-regulated kinase in coronary endothelial cells. Effects were abrogated by a vascular endothelial growth factor (VEGF) antibody, and secretoneurin stimulated VEGF receptors in these cells. Secretoneurin furthermore increased binding of VEGF to endothelial cells, and binding was blocked by heparinase, indicating that secretoneurin stimulates binding of VEGF to heparan sulfate proteoglycan binding sites. Additionally, secretoneurin increased binding of VEGF to its coreceptor neuropilin-1. In endothelial cells, secretoneurin also stimulated fibroblast growth factor receptor-3 and insulin-like growth factor-1 receptor, and in coronary vascular smooth muscle cells, we observed stimulation of VEGF receptor-1 and fibroblast growth factor receptor-3. Exposure of cardiac myocytes to hypoxia and ischemic heart after myocardial infarction revealed increased secretoneurin messenger RNA and protein. CONCLUSIONS: Our data show that secretoneurin acts as an endogenous stimulator of VEGF signaling in coronary endothelial cells by enhancing binding of VEGF to low-affinity binding sites and neuropilin-1 and stimulates further growth factor receptors like fibroblast growth factor receptor-3. Our in vivo findings indicate that secretoneurin may be a promising therapeutic tool in ischemic heart disease.
Authors: Wilfried Schgoer; Markus Theurl; Johannes Jeschke; Arno G E Beer; Karin Albrecht; Roland Gander; Song Rong; Danijela Vasiljevic; Margot Egger; Anna Maria Wolf; Silke Frauscher; Bernhard Koller; Ivan Tancevski; Josef R Patsch; Peter Schratzberger; Hildegunde Piza-Katzer; Andreas Ritsch; Ferdinand H Bahlmann; Reiner Fischer-Colbrie; Dominik Wolf; Rudolf Kirchmair Journal: Circ Res Date: 2009-10-01 Impact factor: 17.367
Authors: Kengo F Kusano; Roberto Pola; Toshinori Murayama; Cynthia Curry; Atsuhiko Kawamoto; Atsushi Iwakura; Satoshi Shintani; Masaaki Ii; Jun Asai; Tengiz Tkebuchava; Tina Thorne; Hideya Takenaka; Ryuichi Aikawa; David Goukassian; Patrick von Samson; Hiromichi Hamada; Young-sup Yoon; Marcy Silver; Elizabeth Eaton; Hong Ma; Lindsay Heyd; Marianne Kearney; William Munger; Jeffery A Porter; Raj Kishore; Douglas W Losordo Journal: Nat Med Date: 2005-10-23 Impact factor: 53.440
Authors: Marja Hedman; Juha Hartikainen; Mikko Syvänne; Joachim Stjernvall; Antti Hedman; Antti Kivelä; Esko Vanninen; Hanna Mussalo; Esa Kauppila; Sakari Simula; Outi Närvänen; Arto Rantala; Keijo Peuhkurinen; Markku S Nieminen; Markku Laakso; Seppo Ylä-Herttuala Journal: Circulation Date: 2003-05-12 Impact factor: 29.690
Authors: Margot Egger; Wilfried Schgoer; Arno G E Beer; Johannes Jeschke; Johannes Leierer; Markus Theurl; Silke Frauscher; Oren M Tepper; Andreas Niederwanger; Andreas Ritsch; Marianne Kearney; Julia Wanschitz; Geoffrey C Gurtner; Reiner Fischer-Colbrie; Guenter Weiss; Hildegunde Piza-Katzer; Douglas W Losordo; Josef R Patsch; Peter Schratzberger; Rudolf Kirchmair Journal: FASEB J Date: 2007-05-15 Impact factor: 5.191
Authors: Patrick R Hannon; Diane M Duffy; Katherine L Rosewell; Mats Brännström; James W Akin; Thomas E Curry Journal: Endocrinology Date: 2018-06-01 Impact factor: 4.736